(UroToday.com) Sarcomatoid renal cell carcinoma (RCC) is a well-described histologic entity often featuring rapid progression and aggressive clinical course when compared with classic clear cell RCC. However, there is a paucity of data assessing the genetic alteration landscape of sarcomatoid RCC. At the 2021 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium, Dr. Gennady Bratslavsky and colleagues presented results of their study assessing whether comprehensive genomic profiling may uncover opportunities for targeting and immunotherapy for sarcomatoid RCC patients that could individualize their treatment and entry into clinical trials.